News

70-year old patient, Mrs. Darlene Bossolla, was diagnosed with inoperable pancreatic cancer last year. Now, part of the TIGeR-PaC clinical trial at UPMC with Dr. Paula Novelli, Mrs. Bossola is reporting her levels to be down and she is feeling great and that she believes this new procedure should be available to everyone.

Based on results of early studies highlighted by this patient’s and other patients’ experiences, RenovoRx initiated and is currently enrolling Stage 3 pancreatic cancer patients in the TIGeR-PaC clinical trial to further test this promising new procedure for pancreatic cancer patients.

The Baptist Health South Studios presents with Dr. Ripal Gandhi, Dr. Raj Narayanan and Dr. Horacio Asbun the state of pancreatic cancer for the patient and treatment options available.

Company’s RenovoCath System Has Received Orphan Drug Designation from the FDA for its Innovative Approach. LOS ALTOS, Calif. – May 23, 2018 – RenovoRx, Inc., a medical technology company developing…

LOS ALTOS, CA – RenovoRx, a Silicon Valley-based medical device company, announced today that two teams of researchers treating patients with advanced non-metastatic pancreatic tumors reported beneficial effects including lengthened…

Aim: A dose escalation study of Gemcitabine for treatment of unresectable pancreatic cancer, using a targeted intra-arterial delivery catheter (RenovoCath™). Methods: 20 patients at two centers were enrolled with a…

LOS ALTOS, Calif., March 30, 2017 /PRNewswire/ — RenovoRx, manufacturer of the RenovoCath adjustable dualballoon infusion catheter, today, announced it has received FDA 510(k) clearance to expand its indications for…

Dr. David Madoff of NewYork-Presbyterian Hospital Weill Cornell Medical Center presented on his experience using novel technologies and techniques in difficult to treat tumor cases at the AIM/VEITH Symposium, November…

RenovoCath™ Catheter Awarded Two Device Patents LOS ALTOS, Calif., Oct. 13, 2016 — RenovoRx, a leading developer of innovative solutions for targeted therapy today announced that the company has received…